Peijia Medical H1 FY26 loss narrows 87.4% to RMB 8.99 million; revenue rises 20.1% to RMB 424.5 million

• Peijia Medical posted revenue of RMB 424.5 million, up 20.1% year over year, in the six months ended June 30, 2026.
• Profit before tax turned positive at RMB 697,000, while loss attributable to owners narrowed 89.14% to RMB 7.59 million.
• EBITDA swung to a positive RMB 47.43 million, while net cash from operating activities rose to RMB 49.41 million.
• TAVR implantations totaled about 2,830; TaurusTrio recorded more than 660 cases, accelerating to 330 cases in July.
• Neurointerventional segment profit climbed 79% to RMB 73.2 million, while the transcatheter valve segment loss narrowed 87.2% to RMB 9.72 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Peijia Medical Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12295134), on August 21, 2026, and is solely responsible for the information contained therein.